Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804245 · ClinicalTrials.gov registry record · Phase 1
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00804245 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants.
The verdict
NCT00804245, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer. PURPOSE: This clinical trial is studying how well C-11 choline PET-CT scan works in finding metastases in patients with newly diagnosed high-risk prostate cancer.
Interventions
- PROCEDURE needle biopsy
- DRUG PET-CT scans supplemented with 11C-Choline tracer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00804245
The ClinicalTrials.gov registry entry for NCT00804245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which needle biopsy is the first listed.
NCT00804245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00804245 about?
NCT00804245 is a clinical study titled "C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer". RATIONALE: New diagnostic procedures, such as C-11 choline PET-CT scan, may be effective in finding cancer that has spread to the bone and lymph nodes in patients with prostate cancer. PURPOSE: This clinical trial is studying how well C-11 choline PET-CT scan works in finding metastases in patients...
What is the current status of trial NCT00804245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00804245?
The interventions under investigation include: needle biopsy (PROCEDURE), PET-CT scans supplemented with 11C-Choline tracer (DRUG).
Who is sponsoring clinical trial NCT00804245?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.